Does Insurance Cover Spravato? What New Jersey Patients Should Know
For many people considering Spravato, the first question is clinical:
Could this treatment help me?
The second question usually arrives a few seconds later:
Will my insurance cover it?
That is understandable. Depression treatment can already involve years of appointments, medication trials, therapy sessions, and unexpected expenses. Patients do not want to begin exploring a new treatment without understanding how the financial side works.
Spravato, the brand name for esketamine nasal spray, is different from IV ketamine in one important respect: it is FDA-approved for treatment-resistant depression in adults. It may be used alone or with an oral antidepressant for that indication. Spravato is also approved, together with an oral antidepressant, for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. (FDA Access Data)
That FDA approval means many commercial insurance plans may provide coverage. But coverage is not automatic, and every health plan has its own rules.
Here is what New Jersey patients should know before starting the process.
Why Spravato May Be Covered When IV Ketamine Is Not
Insurance companies generally base coverage decisions on several factors, including:
FDA-approved indications
The patient’s diagnosis
Previous treatments attempted
Medical necessity
The clinic administering treatment
The health plan’s drug formulary
Prior-authorization requirements
IV ketamine is commonly used off-label for depression. That means ketamine itself is FDA-approved as an anesthetic, but IV ketamine has not received a specific FDA indication for depression.
Spravato has received that depression-related approval. As a result, it is more likely to have a formal insurance pathway.
That does not necessarily make Spravato the better treatment for every patient. It simply means the insurance process may be more clearly defined.
What Does “Treatment-Resistant Depression” Mean?
Most insurance plans require evidence that a patient has treatment-resistant depression before approving Spravato.
In practical terms, this commonly means that the patient has previously tried at least two antidepressant treatments that did not provide adequate relief. Exact requirements vary by plan.
An insurance company may ask for documentation showing:
The antidepressants previously prescribed
The dose and duration of each medication trial
Why a medication was stopped
Whether symptoms improved
The patient’s current diagnosis
Whether psychotherapy or other treatments have been attempted
This is one reason an accurate medication history is so important.
Patients sometimes remember that they tried “several medications” but cannot recall the names, doses, or dates. A psychiatrist, primary-care clinician, pharmacy record, or previous medical chart may help reconstruct that history.
What Is Prior Authorization?
Prior authorization is the insurer’s review process before it agrees to cover a medication or service.
For Spravato, the clinic may need to submit clinical information demonstrating that the patient meets the plan’s criteria.
That submission may include:
Diagnosis
Treatment history
Current symptoms
Previous antidepressant failures
Relevant medical records
The proposed Spravato treatment plan
Prior authorization does not always mean something is wrong. It is a routine part of accessing many specialty medications.
However, it can take time. Requests may be approved, denied, or returned for additional documentation.
A denial is not always the final answer. In some cases, the clinician may submit more information or pursue an appeal.
Why Spravato Must Be Administered in a Certified Setting
Spravato is not mailed to patients for home use.
It is administered in a healthcare setting certified under the Spravato Risk Evaluation and Mitigation Strategy, commonly called the REMS program. Patients are monitored after each treatment because of risks including sedation, dissociation, increases in blood pressure, and impaired alertness. FDA labeling calls for observation for at least two hours, followed by an assessment of whether the patient is clinically stable before leaving. (FDA Access Data)
This requirement affects insurance billing because a Spravato visit can involve more than the medication itself.
Depending on the plan, charges may include:
The medication
Clinical administration
Monitoring
Evaluation and management
Facility-related services
Patients should ask whether each component is covered and whether separate copays, coinsurance, or deductibles apply.
What Will Spravato Cost With Insurance?
There is no single answer.
A patient’s responsibility can depend on:
Deductible status
Copay or coinsurance
In-network versus out-of-network status
Pharmacy benefits
Medical benefits
Employer plan design
Manufacturer assistance eligibility
The frequency of treatment
Two people with the same insurance carrier can have very different benefits because they are enrolled in different employer plans.
The safest approach is to verify benefits before treatment begins rather than relying on a general statement that an insurer “covers Spravato.”
Questions to Ask Before Your First Appointment
When speaking with a clinic or insurance company, ask:
Is Spravato covered under my plan?
Is prior authorization required?
What clinical criteria must I meet?
Is the medication billed through my pharmacy or medical benefit?
Are monitoring and administration billed separately?
What deductible, copay, or coinsurance applies?
Is pre-certification required for each session?
What happens if the initial request is denied?
Are manufacturer support programs available?
Write down the representative’s name, the date of the call, and any reference number provided.
How the Treatment Schedule Affects Cost
For treatment-resistant depression, the FDA-labeled Spravato schedule begins with an induction phase. Treatment is generally administered twice weekly during weeks one through four. Frequency then decreases during subsequent phases, with ongoing treatment individualized according to response and tolerability. (JNJ Labels)
That means patients should understand not only the cost of one session but also the potential cost across the first month and beyond.
A plan that appears affordable for one appointment may feel different when multiple visits are required.
What Happens if Spravato Is Not Covered?
Lack of immediate coverage does not mean a patient is out of options.
Possible next steps may include:
Correcting missing documentation
Submitting an appeal
Requesting a peer-to-peer review
Exploring a different treatment pathway
Reviewing manufacturer support programs
Discussing IV ketamine or another evidence-based treatment
Reassessing the diagnosis and previous medication history
The right treatment decision should still be based on clinical fit, not solely on insurance.
The Bottom Line
Spravato is often more likely to be covered than IV ketamine because it has FDA-approved indications for depression. But approval depends on the patient’s diagnosis, treatment history, insurance plan, prior authorization, and the clinic administering care.
At KetaRevive, the goal is to make the process understandable before treatment begins.
A benefits review cannot promise final payment by an insurer, but it can help patients understand likely requirements, expected costs, and the next appropriate step.
